RIGEL PHARMACEUTICALS, INC. Available-for-sale Securities, Amortized Cost Basis
RIGEL PHARMACEUTICALS, INC. (RIGL) had Available-for-sale Securities, Amortized Cost Basis of $116.28 million as of 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-05-07
- 2019-03-31: Available-for-sale Securities, Amortized Cost Basis $116.28M.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $116.83M.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $103.10M.
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $125.91M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2019-03-31 | $116.28M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $116.83M 10-Q · filed 2019-05-07 |
| 2018-09-30 | $103.10M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $125.91M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $86.72M 10-Q · filed 2018-05-01 |
| 2017-12-31 | $112.46M 10-K · filed 2019-02-28 |
| 2017-09-30 | $62.60M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $75.22M 10-Q · filed 2017-08-01 |
| 2017-03-31 | $88.41M 10-Q · filed 2017-05-02 |
| 2016-12-31 | $65.05M 10-K · filed 2018-03-06 |
| 2016-09-30 | $70.35M 10-Q · filed 2016-11-01 |
| 2016-06-30 | $77.09M 10-Q · filed 2016-08-02 |
| 2016-03-31 | $98.36M 10-Q · filed 2016-05-03 |
| 2015-12-31 | $97.91M 10-K · filed 2017-03-07 |
| 2015-09-30 | $108.20M 10-Q · filed 2015-11-03 |
| 2015-06-30 | $128.15M 10-Q · filed 2015-08-04 |
| 2014-12-31 | $132.96M 10-K · filed 2016-03-08 |
| 2014-09-30 | $148.14M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $163.10M 10-Q · filed 2014-08-05 |
| 2013-12-31 | $202.67M 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |